BiotechTube

OCU410ST

Phase 2/3Recruiting
0 watching 0 views this week📈 Rising
60
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stargardt Disease

Conditions

Stargardt Disease

Trial Timeline

Aug 25, 2023 → Sep 28, 2026

NCT ID
NCT05956626

About OCU410ST

OCU410ST is a phase 2/3 stage product being developed by Ocugen for Stargardt Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05956626. Target conditions include Stargardt Disease.

Hype Score Breakdown

Clinical
22
Activity
15
Company
5
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT05956626Phase 2/3Recruiting

Competing Products

9 competing products in Stargardt Disease

See all competitors
ProductCompanyStageHype Score
MA09-hRPEAstellas PharmaPre-clinical
23
MA09-hRPEAstellas PharmaPhase 1/2
41
avacincaptad pegol + ShamAstellas PharmaPhase 2
52
MA09-hRPEAstellas PharmaPhase 1/2
41
hESC-RPEAstellas PharmaPre-clinical
23
SAR422459SanofiPhase 1/2
40
Long term follow up in all patients who received SAR422459 in previous study TDU13583SanofiPhase 2
51
tinlarebantBelite BioPhase 1/2
38
Tinlarebant + PlaceboBelite BioPhase 3
74

Other Products from Ocugen

Brimonidine Tartrate + PlacebosPhase 3
72
Brimonidine Tartrate + PlacebosPhase 3
72
BBV152Phase 2/3
60
Brimonidine + Brimonidine Mono Therapy + sodium carboxymethylcellulose + Corticosteroid Eye DropPhase 2
47
OCU400 Low Dose + OCU400 Med Dose + OCU400 High Dose + OCU400 Second Eye DosingPhase 1/2
36